JP2011501735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501735A5 JP2011501735A5 JP2010526300A JP2010526300A JP2011501735A5 JP 2011501735 A5 JP2011501735 A5 JP 2011501735A5 JP 2010526300 A JP2010526300 A JP 2010526300A JP 2010526300 A JP2010526300 A JP 2010526300A JP 2011501735 A5 JP2011501735 A5 JP 2011501735A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- substituted
- oxadiazol
- unsubstituted
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carboxy, carbamoyl Chemical group 0.000 claims 74
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000002252 acyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000005236 alkanoylamino group Chemical group 0.000 claims 7
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 5
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 229940124530 sulfonamide Drugs 0.000 claims 5
- 150000003456 sulfonamides Chemical class 0.000 claims 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 claims 3
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 3
- 125000005110 aryl thio group Chemical group 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- OXTKAAXEHMOYSB-UHFFFAOYSA-N 2-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-4,5-diphenyl-1,3-oxazole Chemical compound ClC1=CC=CC(Cl)=C1C1=NC2=CC=C(C=3OC(=C(N=3)C=3C=CC=CC=3)C=3C=CC=CC=3)C=C2N1 OXTKAAXEHMOYSB-UHFFFAOYSA-N 0.000 claims 1
- HNGVSOBRRWEVHO-UHFFFAOYSA-N 2-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-5-[6-(trifluoromethyl)pyridin-3-yl]-1,3,4-oxadiazole Chemical compound C1=NC(C(F)(F)F)=CC=C1C1=NN=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC=CC=2Cl)Cl)O1 HNGVSOBRRWEVHO-UHFFFAOYSA-N 0.000 claims 1
- UBGWQKWLRPICHU-UHFFFAOYSA-N 2-[3,5-dichloro-4-[6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-1h-benzimidazol-2-yl]phenoxy]acetic acid Chemical compound ClC1=CC(OCC(=O)O)=CC(Cl)=C1C1=NC2=CC=C(C=3OC(=NN=3)C=3C=CC(Cl)=CC=3)C=C2N1 UBGWQKWLRPICHU-UHFFFAOYSA-N 0.000 claims 1
- SSCBDEUAEZBUIJ-UHFFFAOYSA-N 2-[4-[6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-1h-benzimidazol-2-yl]-3,5-dimethylphenoxy]acetic acid Chemical compound CC1=CC(OCC(O)=O)=CC(C)=C1C1=NC2=CC=C(C=3OC(=NN=3)C=3C=CC(Cl)=CC=3)C=C2N1 SSCBDEUAEZBUIJ-UHFFFAOYSA-N 0.000 claims 1
- SXYZIDPFWLLKCA-UHFFFAOYSA-N 3,5-dimethyl-4-[6-[5-[3-(trifluoromethyl)anilino]-1,3,4-oxadiazol-2-yl]-1H-benzimidazol-2-yl]phenol Chemical compound CC1=CC(O)=CC(C)=C1C1=NC2=CC=C(C=3OC(NC=4C=C(C=CC=4)C(F)(F)F)=NN=3)C=C2N1 SXYZIDPFWLLKCA-UHFFFAOYSA-N 0.000 claims 1
- LNVAFTZCCRGKBM-UHFFFAOYSA-N 3,5-dimethyl-4-[6-[5-[4-(trifluoromethyl)anilino]-1,3,4-oxadiazol-2-yl]-1H-benzimidazol-2-yl]phenol Chemical compound CC1=CC(O)=CC(C)=C1C1=NC2=CC=C(C=3OC(NC=4C=CC(=CC=4)C(F)(F)F)=NN=3)C=C2N1 LNVAFTZCCRGKBM-UHFFFAOYSA-N 0.000 claims 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims 1
- IUXLNGKBZRFMQT-UHFFFAOYSA-N 3-[4-[6-(5-cyclohexyl-1,3,4-oxadiazol-2-yl)-1h-benzimidazol-2-yl]-3,5-dimethylphenyl]-2,2-dimethylpropanoic acid Chemical compound CC1=CC(CC(C)(C)C(O)=O)=CC(C)=C1C1=NC2=CC=C(C=3OC(=NN=3)C3CCCCC3)C=C2N1 IUXLNGKBZRFMQT-UHFFFAOYSA-N 0.000 claims 1
- TUBPDBIOKLNJTG-UHFFFAOYSA-N 3-[4-[6-(5-methoxy-1,3,4-oxadiazol-2-yl)-1h-indol-2-yl]-3,5-dimethylphenyl]propanoic acid Chemical compound O1C(OC)=NN=C1C1=CC=C(C=C(N2)C=3C(=CC(CCC(O)=O)=CC=3C)C)C2=C1 TUBPDBIOKLNJTG-UHFFFAOYSA-N 0.000 claims 1
- ZMGNWJVVHPJXOV-UHFFFAOYSA-N 3-[4-[6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-1h-indol-2-yl]-3,5-dimethylphenyl]-2,2-dimethylpropanoic acid Chemical compound CC1=CC(CC(C)(C)C(O)=O)=CC(C)=C1C1=CC2=CC=C(C=3OC(=NN=3)C=3C=CC(Cl)=CC=3)C=C2N1 ZMGNWJVVHPJXOV-UHFFFAOYSA-N 0.000 claims 1
- JOYPWBAZXFFWAK-UHFFFAOYSA-N 3-[4-[6-[5-(4-methoxy-2-methylphenyl)-1,3,4-oxadiazol-2-yl]-1h-benzimidazol-2-yl]-3,5-dimethylphenyl]-2,2-dimethylpropanoic acid Chemical compound CC1=CC(OC)=CC=C1C1=NN=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC(CC(C)(C)C(O)=O)=CC=2C)C)O1 JOYPWBAZXFFWAK-UHFFFAOYSA-N 0.000 claims 1
- DZTVXQZHWYUNLE-UHFFFAOYSA-N 3-[4-[6-[5-(4-methoxyanilino)-1,3,4-oxadiazol-2-yl]-1h-benzimidazol-2-yl]-3,5-dimethylphenyl]propanoic acid Chemical compound C1=CC(OC)=CC=C1NC1=NN=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC(CCC(O)=O)=CC=2C)C)O1 DZTVXQZHWYUNLE-UHFFFAOYSA-N 0.000 claims 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims 1
- VCAFQDZGTWSJAS-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-1,3-oxazole Chemical compound C1=CC(Cl)=CC=C1C1=CN=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC=CC=2Cl)Cl)O1 VCAFQDZGTWSJAS-UHFFFAOYSA-N 0.000 claims 1
- FPYKBORVKFNMHS-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-4-methyl-1,3-oxazole Chemical compound CC=1N=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC=CC=2Cl)Cl)OC=1C1=CC=C(Cl)C=C1 FPYKBORVKFNMHS-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 claims 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005333 aroyloxy group Chemical group 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- 150000001556 benzimidazoles Chemical class 0.000 claims 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004470 heterocyclooxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- RTCQRWIAYHAAMH-UHFFFAOYSA-N n-(2-chloropyridin-4-yl)-5-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-1,3,4-oxadiazol-2-amine Chemical compound C1=NC(Cl)=CC(NC=2OC(=NN=2)C=2C=C3NC(=NC3=CC=2)C=2C(=CC=CC=2Cl)Cl)=C1 RTCQRWIAYHAAMH-UHFFFAOYSA-N 0.000 claims 1
- HGPIAKILLFPJJN-UHFFFAOYSA-N n-(2-tert-butylpyridin-4-yl)-5-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-1,3,4-oxadiazol-2-amine Chemical compound C1=NC(C(C)(C)C)=CC(NC=2OC(=NN=2)C=2C=C3NC(=NC3=CC=2)C=2C(=CC=CC=2Cl)Cl)=C1 HGPIAKILLFPJJN-UHFFFAOYSA-N 0.000 claims 1
- RYTPRXOADAOEEW-UHFFFAOYSA-N n-(3-bicyclo[2.2.1]heptanyl)-5-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-1,3,4-oxadiazol-2-amine Chemical compound ClC1=CC=CC(Cl)=C1C1=NC2=CC=C(C=3OC(NC4C5CCC(C5)C4)=NN=3)C=C2N1 RYTPRXOADAOEEW-UHFFFAOYSA-N 0.000 claims 1
- NWZRLVDNPHRTNT-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-5-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-1,3,4-oxadiazol-2-amine Chemical compound N1=CC(Cl)=CC=C1NC1=NN=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC=CC=2Cl)Cl)O1 NWZRLVDNPHRTNT-UHFFFAOYSA-N 0.000 claims 1
- RQIPEQYAIHAQAG-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-5-[2-(2,6-dichlorophenyl)-3h-benzimidazol-5-yl]-1,3,4-oxadiazol-2-amine Chemical compound C1=NC(Cl)=CC=C1NC1=NN=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC=CC=2Cl)Cl)O1 RQIPEQYAIHAQAG-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97606407P | 2007-09-28 | 2007-09-28 | |
| US60/976,064 | 2007-09-28 | ||
| PCT/EP2008/062900 WO2009040410A1 (en) | 2007-09-28 | 2008-09-26 | Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501735A JP2011501735A (ja) | 2011-01-13 |
| JP2011501735A5 true JP2011501735A5 (https=) | 2011-11-10 |
| JP5675359B2 JP5675359B2 (ja) | 2015-02-25 |
Family
ID=39971086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010526300A Expired - Fee Related JP5675359B2 (ja) | 2007-09-28 | 2008-09-26 | Ｄｇａｔ１阻害剤としてのオキサジアゾールおよびオキサゾール置換ベンゾイミダゾールおよびインドール誘導体 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7879850B2 (https=) |
| EP (1) | EP2205595B1 (https=) |
| JP (1) | JP5675359B2 (https=) |
| KR (1) | KR101616133B1 (https=) |
| CN (1) | CN101932576B (https=) |
| AR (1) | AR066169A1 (https=) |
| AU (1) | AU2008303541B2 (https=) |
| BR (1) | BRPI0817272A2 (https=) |
| CA (1) | CA2701053C (https=) |
| CL (1) | CL2008002871A1 (https=) |
| CO (1) | CO6251263A2 (https=) |
| CR (1) | CR11261A (https=) |
| CU (1) | CU20100049A7 (https=) |
| EA (1) | EA019347B1 (https=) |
| EC (1) | ECSP10010051A (https=) |
| ES (1) | ES2525703T3 (https=) |
| IL (1) | IL203797A (https=) |
| MA (1) | MA31707B1 (https=) |
| MX (1) | MX2010003264A (https=) |
| MY (1) | MY151551A (https=) |
| NZ (1) | NZ583285A (https=) |
| PE (1) | PE20090774A1 (https=) |
| TN (1) | TN2010000096A1 (https=) |
| TW (1) | TWI429642B (https=) |
| UA (1) | UA99305C2 (https=) |
| WO (1) | WO2009040410A1 (https=) |
| ZA (1) | ZA201000829B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
| US7749997B2 (en) | 2005-12-22 | 2010-07-06 | Astrazeneca Ab | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors |
| JP2009538892A (ja) | 2006-05-30 | 2009-11-12 | アストラゼネカ アクチボラグ | アセチル補酵素ａジアシルグリセロールアシルトランスフェラーゼの阻害薬としての置換５−フェニルアミノ−１，３，４−オキサジアゾール−２−イルカルボニルアミノ−４−フェノキシ−シクロヘキサンカルボン酸 |
| AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| WO2009112445A1 (en) * | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| US20120022057A1 (en) * | 2009-03-18 | 2012-01-26 | Schering Corporation | Bicyclic compounds as inhibitors of diacyglycerol acyltransferase |
| BR112012016178A2 (pt) | 2009-12-31 | 2015-10-06 | Piramal Healthcare Ltd | inibidores de diacilglicerol aciltransferase |
| MA34097B1 (fr) | 2010-03-30 | 2013-03-05 | Novartis Ag | Utilisations d'inhibiteurs de dgat1 |
| WO2012044567A2 (en) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
| WO2012064569A1 (en) * | 2010-11-08 | 2012-05-18 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
| ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
| WO2013074387A1 (en) * | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
| WO2013169648A1 (en) | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| EP2903985A1 (en) | 2012-10-03 | 2015-08-12 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| WO2014081996A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
| BR112015011982A8 (pt) * | 2012-11-23 | 2019-10-08 | Glaxosmithkline Llc | compostos inibidores de diacilglicerol aciltransferase, composição farmacêutica compreendendo estes e usos destes |
| CN103087045B (zh) * | 2013-01-11 | 2015-08-12 | 上海交通大学 | 一种苯并咪唑类杂环化合物、药物组合物及其用途 |
| CN104672144A (zh) * | 2015-02-13 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 一种环丙基酰肼和硝基苯类gpr119激动剂、制备方法及其用途 |
| CN104610152A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类环丙基酰肼类gpr119激动剂、制备方法及其用途 |
| IL277332B2 (en) | 2018-03-16 | 2025-01-01 | Anji Pharmaceuticals Inc | Preparations and methods for treating severe constipation |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド |
| US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| CN117466863B (zh) * | 2022-07-20 | 2026-03-24 | 盛睿泽华医药科技（苏州）有限公司 | 含芳香族取代基的苯并咪唑化合物及其制备方法和用途 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU722514B2 (en) | 1995-12-28 | 2000-08-03 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| KR100979988B1 (ko) | 2001-08-13 | 2010-09-03 | 얀센 파마슈티카 엔.브이. | 2-아미노-4,5-삼치환 티아졸릴 유도체 |
| WO2008011131A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| KR100772297B1 (ko) | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
| EP1572637A1 (en) | 2002-12-11 | 2005-09-14 | Eli Lilly And Company | Novel mch receptor antagonists |
| US7572922B2 (en) | 2003-01-27 | 2009-08-11 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| JP3878625B2 (ja) * | 2003-06-20 | 2007-02-07 | 松下電器産業株式会社 | 振幅調整回路、モータ駆動制御装置、振幅調整方法、及びモータ駆動制御方法 |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| EP1653969A4 (en) * | 2003-08-07 | 2006-12-20 | Japan Tobacco Inc | PYRROLO 1,2-B PYRIDAZINE DERIVATIVES |
| WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
| CA2555073A1 (en) | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Amino heterocyclic modulators of chemokine receptor activity |
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| WO2006004200A1 (ja) | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| JP2008516978A (ja) | 2004-10-15 | 2008-05-22 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用 |
| WO2006060109A1 (en) | 2004-10-29 | 2006-06-08 | Merck & Co., Inc. | 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
| US20090048258A1 (en) | 2005-02-01 | 2009-02-19 | Masaki Ogino | Amide Compound |
| KR20080000652A (ko) | 2005-04-19 | 2008-01-02 | 바이엘 파마슈티칼스 코포레이션 | 아릴 알킬산 유도체 및 그의 용도 |
| WO2006120125A1 (en) | 2005-05-10 | 2006-11-16 | F. Hoffmann-La Roche Ag | Diacylglycerol acyltransferase inhibitors |
| KR20080015113A (ko) | 2005-06-11 | 2008-02-18 | 아스트라제네카 아베 | Ｄｇａｔ 억제제로서의 옥사디아졸 유도체 |
| JP2009505962A (ja) | 2005-07-29 | 2009-02-12 | バイエル・ヘルスケア・エルエルシー | 肥満を治療するためのビフェニルアミノ酸誘導体の製造および使用 |
| US7816542B2 (en) | 2005-08-15 | 2010-10-19 | Irm Llc | Compounds and compositions as TPO mimetics |
| EP1960382A1 (en) | 2005-11-03 | 2008-08-27 | ChemBridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| CA2630269C (en) | 2005-11-28 | 2011-07-05 | F. Hoffmann-La Roche Ag | Inhibitors of diacyglycerol acyltransferase (dgat) |
| US7749997B2 (en) | 2005-12-22 | 2010-07-06 | Astrazeneca Ab | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors |
| US20080064717A1 (en) | 2006-05-19 | 2008-03-13 | Rajesh Iyengar | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| US20080015227A1 (en) | 2006-05-19 | 2008-01-17 | Kym Philip R | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| JP2009538892A (ja) | 2006-05-30 | 2009-11-12 | アストラゼネカ アクチボラグ | アセチル補酵素ａジアシルグリセロールアシルトランスフェラーゼの阻害薬としての置換５−フェニルアミノ−１，３，４−オキサジアゾール−２−イルカルボニルアミノ−４−フェノキシ−シクロヘキサンカルボン酸 |
| WO2007138304A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
| JP2009539816A (ja) | 2006-06-06 | 2009-11-19 | アストラゼネカ アクチボラグ | 化学化合物 |
| ES2359653T3 (es) | 2006-06-08 | 2011-05-25 | Astrazeneca Ab | Bencimidazoles y su uso para el tratamiento de la diabetes. |
| GB0611507D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611506D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611552D0 (en) | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| WO2008011130A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| US7915299B2 (en) | 2006-11-15 | 2011-03-29 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| SG177144A1 (en) | 2006-11-29 | 2012-01-30 | Abbott Lab | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| WO2008099221A1 (en) | 2007-02-15 | 2008-08-21 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
| GB0707662D0 (en) | 2007-04-20 | 2007-05-30 | Astrazeneca Ab | Chemical compounds |
| NZ580662A (en) | 2007-04-30 | 2012-01-12 | Abbott Lab | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders |
| BRPI0810719A8 (pt) | 2007-04-30 | 2016-03-08 | Abbott Lab | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 |
| US8153644B2 (en) | 2007-05-22 | 2012-04-10 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8115011B2 (en) | 2007-05-22 | 2012-02-14 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8058299B2 (en) | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| AU2008253118B2 (en) | 2007-05-22 | 2013-11-21 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| ES2558152T3 (es) | 2007-06-08 | 2016-02-02 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| AU2008258560C1 (en) | 2007-06-08 | 2014-04-10 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| ES2536406T3 (es) | 2007-06-08 | 2015-05-25 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| WO2009011285A1 (ja) | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | ヘテロアリールベンゼン化合物 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| WO2009024821A2 (en) | 2007-08-17 | 2009-02-26 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
| US20090076275A1 (en) | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
| AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| WO2009071483A1 (en) | 2007-12-07 | 2009-06-11 | Via Pharmaceuticals, Inc. | 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors |
| EP2234978B1 (en) | 2007-12-20 | 2015-02-25 | AstraZeneca AB | Carbamoyl compounds as dgat1 inhibitors 190 |
| MX2010010471A (es) | 2008-03-26 | 2010-10-20 | Daiichi Sankyo Co Ltd | Derivado de tetrahidroisoquinolina novedoso. |
| ES2617619T3 (es) | 2008-06-05 | 2017-06-19 | Janssen Pharmaceutica, N.V. | Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR |
| EP2559455A1 (en) * | 2008-07-15 | 2013-02-20 | Novartis AG | Heteroaryl derivatives as DGAT1 inhibitors |
-
2008
- 2008-09-25 AR ARP080104165A patent/AR066169A1/es not_active Application Discontinuation
- 2008-09-26 NZ NZ583285A patent/NZ583285A/en not_active IP Right Cessation
- 2008-09-26 PE PE2008001688A patent/PE20090774A1/es not_active Application Discontinuation
- 2008-09-26 EP EP08804779.0A patent/EP2205595B1/en active Active
- 2008-09-26 AU AU2008303541A patent/AU2008303541B2/en not_active Ceased
- 2008-09-26 ES ES08804779.0T patent/ES2525703T3/es active Active
- 2008-09-26 MY MYPI20100653 patent/MY151551A/en unknown
- 2008-09-26 US US12/239,029 patent/US7879850B2/en not_active Expired - Fee Related
- 2008-09-26 MX MX2010003264A patent/MX2010003264A/es active IP Right Grant
- 2008-09-26 UA UAA201003529A patent/UA99305C2/ru unknown
- 2008-09-26 CN CN200880104322.3A patent/CN101932576B/zh not_active Expired - Fee Related
- 2008-09-26 EA EA201000428A patent/EA019347B1/ru not_active IP Right Cessation
- 2008-09-26 TW TW097137382A patent/TWI429642B/zh not_active IP Right Cessation
- 2008-09-26 CA CA2701053A patent/CA2701053C/en not_active Expired - Fee Related
- 2008-09-26 JP JP2010526300A patent/JP5675359B2/ja not_active Expired - Fee Related
- 2008-09-26 BR BRPI0817272-2A patent/BRPI0817272A2/pt not_active Application Discontinuation
- 2008-09-26 KR KR1020107006598A patent/KR101616133B1/ko not_active Expired - Fee Related
- 2008-09-26 CL CL2008002871A patent/CL2008002871A1/es unknown
- 2008-09-26 WO PCT/EP2008/062900 patent/WO2009040410A1/en not_active Ceased
-
2010
- 2010-02-04 ZA ZA2010/00829A patent/ZA201000829B/en unknown
- 2010-02-08 IL IL203797A patent/IL203797A/en not_active IP Right Cessation
- 2010-02-10 CR CR11261A patent/CR11261A/es not_active Application Discontinuation
- 2010-02-25 TN TNP2010000096A patent/TN2010000096A1/fr unknown
- 2010-03-17 CU CU2010000049A patent/CU20100049A7/es not_active IP Right Cessation
- 2010-03-17 MA MA32702A patent/MA31707B1/fr unknown
- 2010-03-26 EC EC2010010051A patent/ECSP10010051A/es unknown
- 2010-04-19 CO CO10045481A patent/CO6251263A2/es active IP Right Grant
- 2010-12-09 US US12/964,170 patent/US8217065B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501735A5 (https=) | ||
| US7879850B2 (en) | Organic compounds | |
| RU2457207C2 (ru) | Активаторы глюкокиназы | |
| RU2008110949A (ru) | Соединения и композиции-иммуносупрессанты | |
| RU2018138707A (ru) | Замещенные гетероарилом пиридины и способы применения | |
| JP2019517455A5 (https=) | ||
| RU2015111133A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP6668329B2 (ja) | 新規オキサジアゾール誘導体及びこれを含有する医薬 | |
| JP2016518399A5 (https=) | ||
| JP2007505877A5 (https=) | ||
| JP2014521653A5 (https=) | ||
| JP2011520896A5 (https=) | ||
| JP2009544742A5 (https=) | ||
| JP2011502958A5 (https=) | ||
| JP2014526500A5 (https=) | ||
| JP2014513120A5 (https=) | ||
| JP2015503529A5 (https=) | ||
| RU2008151762A (ru) | Adlh-2 ингибиторы для лечения аддикции | |
| RU2010150786A (ru) | Пирролопиридины как ингибиторы киназы | |
| JP2011503230A5 (https=) | ||
| JP2014518214A5 (https=) | ||
| RU2009117475A (ru) | Соединения, модулирующие активность c-fms и/или c-kit, и их применения | |
| JP2005513026A5 (https=) | ||
| JP2017508766A5 (https=) | ||
| HRP20160539T1 (hr) | Antagonisti trpv4 |